Rigontec, a Germany-based RNA therapeutics developer backed by pharmaceutical firm Boehringer Ingelheim, yesterday agreed to an acquisition by US-based pharmaceutical company Merck for up to €464m ($554m). Merck, through an unnamed subsidiary, will make an upfront cash payment of €115m, with the remaining €349m dependent on clinical, development, regulatory and commercial milestones. The deal is…
- News & Analysis
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Deal Data
- Community & Events
Merck diagnoses $554m Rigontec acquisition
Sep 7, 2017 • Thierry Heles
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Featured ContentFUNDING ROUND DATA Which corporates are backing which startups? Search our corporate deal database.
FUNDING ROUND DATA
Which corporates are backing which startups? Search our corporate deal database.PEOPLE Make your nominations for the Global Corporate Venturing Rising Stars and Emerging Leaders Awards
Make your nominations for the Global Corporate Venturing Rising Stars and Emerging Leaders AwardsEventsWebinar: Reaching for the sun - Is it time to invest in fusion?Top News
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.test reg